Shires Income PLC - investor with "diversified portfolio" consisting mainly of UK equities - Shareholders approve scheme to combine with Aberdeen Equity Income Trust PLC, with 97.28% voting in favour.

Marula has also provided an update on its agency framework contract with Baosteel Resources South Africa (Pty) Ltd. The deal outlines the purchase and sale of manganese from the Kilifi Manganese ...

(Alliance News) - Tullow Oil PLC on Monday said it has received another chunk of cash under an agreement announced last year, and said if oil prices stay elevated, pre-financing cash flow guidance ...

Shares in Stack BTC surged 67% to 10.25 pence each on Monday morning on the Aquis Stock Exchange in London. It noted the fundraise comprised an equity participation from Nigel Farage and ...

Fears of inflation triggered a sharp sell-off in gilt markets, while Ebury analyst Matthew Ryan noted that swap markets have moved from fully pricing in two Bank of England cuts in 2026 to now seeing ...

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: ...

(Alliance News) - CQS UK LLP announced on Monday that portfolio managers Keith Watson and Robert Crayfourd have tendered their resignations and will leave the company in three months.

The consideration comprises, USD200,000 paid on completion and USD400,000 set off against a subscription by Appian for 5.4 million shares at 5.5 pence each. In addition, USD1.5 million will be paid, ...

(Alliance News) - M&C Saatchi PLC on Monday said Chief Executive Officer Zaid Al-Qassab will step down, with AdvancedAdvT Ltd Executive Chair Vin Murria set to join the board.

Kefi added that it continues to have "more than enough capital on offer" for Tulu Kapi's development, having received commitments covering USD310 million of the USD330 million approved budget as of ...

(Alliance News) - SkinBioTherapeutics on Monday confirmed the appointment of Interim Chief Executive Officer Rachel Parsonage to its board after completing regulatory due diligence.

In return, London-based pharmaceutical firm GSK will receive USD300 million upfront from Alfasigma, and a further USD100 million, upon US Food & Drug Administration approval for linerixibat, which is ...